FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

_			
Vashington,	D.C.	20549	

OMB APPF	OMB APPROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

	Check this box if no longer subject
١	to Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MILANO VINCENT					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX									all app Direc	ionship of Reporting all applicable) Director		10% Ov	vner	
(Last) (First) (Middle) 4505 EMPEROR BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 05/20/2024										Officer (give title below)			Other (specify below)	
SUITE 200				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) DURHA	M NO	2	7703										X Form filed by One Reporting Pe Form filed by More than One Re Person				•	- 1	
(City)	(St	ate) (Z	ľip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Date		ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			, 4 and Se Be Ov		Securities Beneficially Owned Following		r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	ount (A) o		,	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 05/20/2					2024				P		15,000	A	\$6.2	.25 ⁽¹⁾ 66,997			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	e Conversion Date Execution Date, Trar		Transa Code (6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		nt		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y [6]	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	ode V (A) (D)		(D)	Date Expiration Exercisable Date Title		Number of Shares								

Explanation of Responses:

1. The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from \$6.23 to \$6.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

> /s/ Alane P. Barnes, by power of attorney

05/22/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.